PUBLIC COMPANY

$EVMNEvommune, Inc.

Palo Alto, CA, USupdated 1mo ago

SEC EDGAR Yahoo Finance

community read0 votes

pipeline

1

marketed

0

phase 3

0

catalysts ytd

0

approvals ytd

0

recalls ytd

0

Pipeline(1)

pipeline depth1 products

1Phase 2

Phase 2

EVO-756

Chronic Inducible Urticaria

Upcoming

no upcoming catalysts on record

Recent(90d)

nothing in the last 90 days

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view Evommune, Inc. jobs →

News

no news has mentioned this company yet

$EVMN

Active trials

phase2Phase 2b Study of EVO756 in Adults With Atopic Dermatitisrecruitingn=120
phase2Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)active not recruitingn=160
phase2Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitiscompletedn=71
phase2A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticariacompletedn=30
phase2Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitiscompletedn=119

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Insider activity

source: SEC Form 4

routine RSU / option mechanics (6)

Apr 16, 26grantPatel Jeegar Pravinkumar · Chief Scientific Officer69,315 sh
Apr 16, 26grantDrew Janice Suzann · Chief of Dev. Operations73,892 sh
Apr 16, 26grantBauer Eugene · Chief Medical Officer51,117 sh
Apr 16, 26grantCarver Kyle · Chief Financial Officer98,946 sh
Apr 16, 26grantMoss Gregory S.

· Chief Business & Legal Officer

115,279 sh

Apr 16, 26grantPena Luis C. · President & CEO291,420 sh

Data sources

SEC EDGAR

last refreshed 24m ago

Found something off?